GSK
July 30, 2025 - AI Summary
Overvalued by 11.6% based on the discounted cash flow analysis.
Market cap | $88.40 Billion |
---|---|
Enterprise Value | $85.38 Billion |
Dividend Yield | $1.65 (3.60%) |
Earnings per Share | $1.26 |
Beta | 0.29 |
Outstanding Shares | 2,031,500,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 19.33 |
---|---|
PEG | 83.98 |
Price to Sales | 2.89 |
Price to Book Ratio | 6.19 |
Enterprise Value to Revenue | 2.7 |
Enterprise Value to EBIT | 16.21 |
Enterprise Value to Net Income | 24 |
Total Debt to Enterprise | 0.01 |
Debt to Equity | 0.04 |
No data
No data